drugset / Trial / NCT07700875
A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare the antihypertensive effect of QR12000 Compound Tablets with its single component, QR01019 potassium salt, and with valsartan in patients with moderate to severe essential hypertension.
Timeline
- Start
- 2022-12-29
- Primary completion
- 2023-08-20
- Completion
- 2023-09-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZILSARTAN MEPIXETIL | Small molecule | 50 mg | — |
| Subject | QR12000 Compound Tablets | Unknown | 75 mg | — |
| Subject | QR12000 Compound Tablets | Unknown | 150 mg | — |
| Comparator | Sacubitril / valsartan | Unknown | 200 mg | — |
| Comparator | Valsartan | Small molecule | 160 mg | — |